Skip to main content
. 2025 Dec 24;16:1. doi: 10.1186/s13550-025-01332-5

Fig. 1.

Fig. 1

Whole-body maximum-intensity projections over time after [89Zr]Zr-girentuximab administration. Mass dose of 10 mg girentuximab demonstrating a ccRCC tumor in right kidney (red arrow) at 0.5 hours with an increased tumor to background ratio over time. Standardized uptake values were normalized to body weight